After a desperate, deadly year of coronavirus, the UK's vaccination programme has delivered first doses to 15 million of the oldest and most vulnerable.
Every vaccine bought for the UK has been on the assumption that just 30 million people - less than half the population - will get it.
Two COVID-19 vaccines being tested in the UK have moved on to the third phase of trials, marking a significant step forward in the development process.
Professor Peter Horby, Professor of Emerging Infectious Diseases and Global Health, has said that dexamethasone is the 'only drug shown to reduce mortality'.
Professor Jonathan Heeney explains why we need a vaccine against the new COVID-19 coronavirus and how his team is using new technology developed for influenza and Ebola viruses to target the new infection.